Publications
  1.  

1.      Bhattacharyya S, Pradhan K, Campbell N, Mazdo J, Vasantkumar A, Maqbool S, Bhagat TD, Gupta S, Suzuki M, Yu Y, Greally JM, Steidl U, Bradner J, Dawlaty M, Godley L, Maitra A, Verma A, “Altered hydroxymethylation is seen at regulatory regions in pancreatic cancer and regulates oncogenic pathways.” Genome Res, 2017, Oct 6. PMID: 28986391 

2.      Bhagat TD, Chen S, Bartenstein M, Barlowe AT, Von Ahrens D, Choudhary GS, Tivnan P, Amin E, Marcondes M, Sanders MA, Hoogenboezem RM, Kambhampati S, Ramachandra N, Mantzaris I, Sukrithan V, Laurence R, Lopez R, Bhagat P, Giricz O, Sohal D, Wickrema A, Yeung C, Gritsman K, Aplan P, Hochedlinger K, Yu Y, Pradhan K, Zhang J, Greally JM,  Mukherjee SM, Pellagatti A, Boultwood J, Will B, Steidl U, Raaijmakers MHGP, Deeg HJ, Kharas MG, Verma A, “Wnt/ß-catenin activation by epigenetically aberrant stroma drives myelodysplastic syndrome.”  Cancer Research Jul, 2017, PMID: 28684528  

3.      Reyna DE, Garner TP, Lopez A, Kopp F, Choudhary GS, Sridharan A, Narayanagari SR, Mitchell K, Dong B, Bartholdy BA, Walensky LD, Verma A, Steidl U, Gavathiotis E. Direct “Activation of BAX by BTSA1 Overcomes Apoptosis Resistance in Acute Myeloid Leukemia.”  Cancer Cell 2017 Oct 9.PMID: 29017059  

4.      Antony-Debré I, Paul A, Leite J, Mitchell K, Kim HM, Carvajal LA, Todorova TI, Huang K, Kumar A, Farahat AA, Bartholdy B, Narayanagari SR, Chen J, Ambesi-Impiombato A, Ferrando AA, Mantzaris I, Gavathiotis E, Verma A, Will B, Boykin DW, Wilson WD, Poon GM, Steidl U., “Pharmacological inhibition of the transcription factor PU.1 in leukemia.”  J Clin Invest 2017 Oct 30, PMID: 29083320  

5.      Yue L, Bartenstein M, Zhao W, Ho W, Murdun C, Mailloux AW, Zhang L, Budhakoti A, Pradhan K, Rapaport F, Wang H, Shao Z, Steidl U, Levine RL, Zhao ZJ*, Verma A*, Epling-Burnette PK* (*Co-Corresponding), “Efficacy of ALK5 Inhibition in Myelofibrosis.” JCI Insight Apr 6;2(7):e90932. 2017 PMID: 28405618  

6.      Yip BH, Steeples V, Repapi E, Armstrong RN, Llorian M, Roy S, Shaw J, Dolatshad H, Taylor S, Verma A, Bartenstein M, Vyas P, Cross NC, Malcovati L, Cazzola M, Hellström-Lindberg E, Ogawa S, Smith CW, Pellagatti A, Boultwood J, “The U2AF1S34F mutation induces lineage-specific splicing alterations in myelodysplastic syndromes.”   J Clin Invest. 2017 Jun 1;127(6):2206-2221. PMID: 28436936  

7.      Bhagat TD, Zou Y, Huang S, Park J, Palmer MB, Hu C, Li W, Shenoy N, Giricz O, Choudhary G, Yu Y, Ko YA, Izquierdo MC, Park ASD, Vallumsetla N, Laurence R, Lopez R, Suzuki M, Pullman J, Kaner J, Gartrell B, Hakimi AA, Greally JM, Patel B, Benhadji K, Pradhan K, Verma A*, Susztak K* (*Co-Corresponding), “Notch pathway is activated via genetic and epigenetic alterations and is a therapeutic target in clear cell renal cancer.” JBC 2016, Dec 1. PMID: 2790905  

8.      Bachegowda L, Morrone K, Winski SL, Mantzaris I, Bartenstein M, Ramachandra N, Giricz O, Sukrithan V, Nwankwo G, Shahnaz S , Bhagat T, Bhattacharyya S, Assal A, Shastri A,  Gordon-Mitchell S, Pellagatti A, Boultwood J, Schinke C, Yu Y, Guha C, Rizzi J, Garrus J, Brown S, Wollenberg L, Hogeland G, Wright D, Munson M`, Rodriguez M, Gross S, Chantry D, Zou Y, Platanias L, Burgess LE, Pradhan K, Steidl U, Verma A,  “Pexmetinib: a novel dual inhibitor of Tie-2 and p38 MAPK with efficacy in preclinical models of myelodysplastic syndromes and acute myeloid leukemia.”  Cancer Res 2016 Jun 10. PMID: 27287719  

9.      Wijetunga NA, Pascual M, Tozour J, Delahaye F, Alani M, Adeyeye M, Wolkoff AW, Verma A, Greally JM., “A pre-neoplastic epigenetic field defect in HCV-infected liver at transcription factor binding sites and polycomb targets.” Oncogene. 2016 Oct 10. PMID: 27721404  

10.  Mantzaris I, Yu Y, Msaouel P, Lam AP, Janakiram M, Friedman EW, Steidl U, Verma A., “Analysis of overall survival in a large multiethnic cohort reveals absolute neutrophil count of 1,100 as a novel prognostic cutoff in African Americans.” Oncotarget. 2016 Apr 26. PMID: 27144332  

11.  Zell M, Assal A, Derman O, Kornblum N, Battini R, Wang Y, Narasimhulu DM, Mantzaris I, Shastri A, Verma A, Ye H, Braunschweig I, Janakiram M,  “Adult T-Cell leukemia/lymphoma in the Caribbean cohort is a distinct clinical entity with dismal response to conventional chemotherapy.” Oncotarget. 2016 Jun 22. PMID: 27341021  

12.  Goel S, Hall J, Pradhan K, Hirsch C, Przychodzen B, Shastri A, Mantzaris I,  Janakiram M, Battini R, Kornblum N, Derman O, Gritsman K, Al-Hafidh J, Wang Y, Halmos B, Steidl U, Maciejewski J, Braunschweig I, Verma A, “High Prevalence and Allele Burden Independent Prognostic Importance of p53 Mutations in an Inner-City MDS/AML Cohort,”  Leukemia 2016 Apr 29. PMID: 27125205  

13.  Taggart J, Ho TC, Amin E, Xu H, Barlowe TS, Perez AR, Durham BH, Tivnan P, Okabe R, Chow A, Vu L, Park SM, Prieto C, Famulare C, Patel M, Lengner CJ, Verma A, Roboz G, Guzman M, Klimek VM, Abdel-Wahab O, Leslie C, Nimer SD, Kharas MG, “MSI2 is required for maintaining activated myelodysplastic syndrome stem cells.” Nat Commun. 2016 Feb 22;7:10739. PMID: 26898884  

14.  Platzbecker U, Wong RS, Verma A, Abboud C, Araujo S, Chiou TJ, Feigert J, Yeh SP, Götze K, Gorin NC, Greenberg P, Kambhampati S, Kim YJ, Lee JH, Lyons R, Ruggeri M, Santini V, Cheng G, Jang JH, Chen CY, Johnson B, Bennett J, Mannino F, Kamel YM, Stone N, Dougherty S, Chan G, Giagounidis A., “Safety and tolerability of eltrombopag versus placebo for treatment of thrombocytopenia in patients with advanced myelodysplastic syndromes or acute myeloid leukaemia: a multicentre, randomised, placebo-controlled, double-blind, phase 1/2 trial.” Lancet Haematol. 2015 Oct;2(10):e417-26. PMID: 26686043  

15.  Sundaravel S, Duggan R, Bhagat TD, Ebenezer D, Liu H, Yu Y, Bartenstein M, Unnikrishnan M, Karmakar S, Liu TC, Torregroza I, Quenon T, Anastasi J, McGraw K, Pellagatti A, Boultwood J, Yajnik V, Artz A, Le Beau M, Steidl U, List A, Evans T*, Verma A*, Wickrema A*. (*Co-Corresponding) “Reduced DOCK4 Expression Leads to Erythroid Dysplasia in Myelodysplastic Syndromes.” Proc Natl Acad Sci USA.2015; In Press  

16.  Schinke C, Giricz O, Li W, Shastri A, Gordon S, Barreryo L, Bhagat T, Bhattacharyya S, Ramachandra N, Bartenstein M, Pellagatti A, Boultwood J, Wickrema A, Yu Y, Will W, Wei S, Steidl U*, Verma A*, * co-corresponding authors “IL8-CXCR2 pathway inhibition as a novel therapeutic strategy against MDS and AML stem cells.” Blood. 2015, Mar 25. PMID: 25810490  

17.  Okoye-Okafor UC, Bartholdy B, Cartier J, Gao EN, Pietrak B, Rendina AR, Rominger C, Quinn C, Smallwood A, Wiggall KJ, Reif AJ, Schmidt SJ, Qi H, Zhao H, Joberty G, Faelth-Savitski M, Bantscheff M, Drewes G, Duraiswami C, Brady P, Groy A, Narayanagari SR, Antony-Debre I, Mitchell K, Wang HR, Kao YR, Christopeit M, Carvajal L, Barreyro L, Paietta E, Makishima H, Will B, Concha N, Adams ND, Schwartz B, McCabe MT, Maciejewski J, Verma A, Steidl U, “New IDH1 mutant inhibitors for treatment of acute myeloid leukemia.” Nature Chem Biol. 2015 Oct 5. PMID: 26436839  

18.  Will B, Vogler TO, Narayanagari S, Bartholdy B, Todorova TI, Ferreira M, Chen J, Yu Y, Mayer J, Barreyro L, Carvajal L, Ben Neriah D, Roth M, van Oers J, Schaetzlein S, McMahon C, Edelmann W, Verma A, Steidl U, “Minimal reduction of PU.1 is sufficient to induce a preleukemic state and promote development of acute myeloid leukemia .” Nature Medicine, 2015 Sep 7. PMID: 26343801  

19.  Vardabasso C, Gaspar-Maia A, Hasson D, Pünzeler S, Valle-Garcia D, Straub T, Keilhauer EC, Strub T, Dong J, Panda T, Chung CY, Yao JL, Singh R, Segura MF, Fontanals-Cirera B, Verma A, Mann M, Hernando E, Hake SB, Bernstein E. “Histone Variant H2A.Z.2 Mediates Proliferation and Drug Sensitivity of Malignant Melanoma.” Mol Cell. 2015 Jun 3. PMID: 26051178  

20.  PAK1 Pandolfi A, Stanley RF, Yu Y, Bartholdy B, Pendurti G, Gritsman K, Boultwood J, Chernoff J, Verma A, Steidl U, “PAK1 is a therapeutic target in acute myeloid leukemia and myelodysplastic syndrome.” Blood. 2015 Jul 13. PMID: 26170031  

21.  Cabrero M, Yu Y, Verma A, Yang H, Colla S, Jia Y, Zheng H, Bohannan Z, Ganan-Gomez I, Futreal A, Takahashi K, Chin L, Kantarjian H, Pellagatti A, Bowman T, Boultwood J, Garcia-Manero G, Wei Y, “Downregulation of Protection of Telomeres 1 expression in myelodysplastic syndromes with 7q deletion.” Br J Haematol. 2015 Jun 24. PMID: 26105212  

22.  Cimmino L, Dawlaty MM, Ndiaye-Lobry D, Yap YS, Bakogianni S, Yu Y, Bhattacharyya S, Shaknovich R, Geng H, Lobry C, Mullenders J, King B, Trimarchi T, Aranda-Orgilles B, Liu C, Shen S, Verma A, Jaenisch R, Aifantis I, “TET1 is a tumor suppressor of hematopoietic malignancy.” Nat Immunol. 2015 Apr 13. PMID: 25867473  

23.  Saleiro D, Mehrotra S, Kroczynska B, Beauchamp EM, Lisowski P, Majchrzak-Kita B, Bhagat TD, Stein BL, McMahon B, Altman JK, Kosciuczuk EM, Baker DP, Jie C, Jafari N, Thompson CB, Levine RL, Fish EN, Verma A, Platanias LC, “Central Role of ULK1 in Type I Interferon Signaling.” Cell Reports 2015, Apr 28;11(4):605-17. PMID: 25892232  

24.  Sassano A, Mavrommatis E, Arslan AD, Kroczynska B, Beauchamp EM, Khuon S, Chew TL, Green KJ, Munshi HG, Verma AK, Platanias LC, “Human Schlafen 5 (SLFN5) is a Regulator of Motility and Invasiveness of Renal Cell Carcinoma Cells.” Mol Cell Biol. 2015 May 26. PMID: 26012550  

25.  Gerstung M, Pellagatti A, Malcovati L, Giagounidis A, Porta MG, Jädersten M, Dolatshad H, Verma A, Cross NC, Vyas P, Killick S, Hellström-Lindberg E, Cazzola M, Papaemmanuil E, Campbell PJ, Boultwood J, “Combining gene mutation with gene expression data improves outcome prediction in myelodysplastic syndromes.” Nat Commun. 2015 Jan 9;6:5901. PMID: 25574665  

26.  Caescu CI, Guo X, Tesfa L, Bhagat TD, Verma A, Zheng D, Stanley ER, “Colony stimulating factor-1 receptor signaling networks inhibit mouse macrophage inflammatory responses by induction of microRNA-21.” Blood. 2015 Jan 8. PMID: 25573988  

27.  Sridharan A, Jain R, Bachhuber MA, Yu Y, Ramesh Kh, Gundabolu K, Friedman EW, Verma AK, “Epidemiologic study of myelodysplastic syndromes in a multiethnic, inner city cohort.” Exp Hematol Oncol. 2014 Aug 23;3:22. PMID: 25170429  

28.  Shrivastava MS, Hussain Z, Giricz O, Shenoy N, Polineni R, Maitra A, Verma A, “Targeting chemokine pathways in esophageal adenocarcinoma.” Cell Cycle. 2014 Nov 1;13(21):3320-7. PMID: 25485576  

29.  Hu C, Mohtat D, Yu Y, Ko YA, Shenoy N, Bhattacharyya S, Izquierdo MC, Park AS, Giricz O, Vallumsetla N, Gundabolu K, Ware K, Bhagat T, Suzuki M, Pullman J, Liu SX, Greally J, Susztak K, Verma A, “Kidney cancer is characterized by aberrant methylation of tissue specific enhancers that are prognostic for overall survival.” Clin Cancer Res. 2014 Jun 10. PMID: 24916699  

30.  Mariani CJ, Vasanthakumar A, Madzo J, Yesilkanal A, Bhagat T, Yu Y, Bhattacharyya S, Wenger R, Cohn S, Nanduri J, Verma A, Prabhakar N, Godley LA, “TET1-Mediated Hydroxymethylation Facilitates Hypoxic Gene Induction in Neuroblastoma.” Cell Rep. 2014 May 14. PMID: 24835990  

31.  Keerthivasan G, Mei Y, Zhao B, Zhang L, Harris CE, Gao J, Basiorka AA, Schipma MJ, McElherne J, Yang J, Verma AK, Pellagatti A, Boultwood J, List AF, Williams DA, Ji P, “ Aberrant overexpression of CD14 on granulocytes sensitizes the innate immune response in mDia1 heterozygous del(5q) myelodysplastic syndromes.” Blood. 2014 Jun 2. PMID: 24891322  

32.  Tamari R, Schinke C, Bhagat T, Roth M, Braunschweig I, Will B, Steidl U, Verma A, “Eltrombopag can overcome the anti-megakaryopoietic effects of lenalidomide without increasing proliferation of the malignant myelodysplastic syndrome/acute myelogenous leukemia clone.” Leuk Lymphoma, 2014 Dec;55(12):2901-6.PMID: 24650011  

33.  Bartholdy B, Christopeit M, Will B, Mo Y, Barreyro L, Yu Y, Bhagat T, Okoye-Okafor U, Todorova T, Greally J, Levine RL, Melnick A, Verma A*, Steidl U. *Co-Corresponding, “A human hematopoietic stem cell-commitment related DNA cytosine methylation signature is prognostic for overall survival in acute myeloid leukemia.” Journal of Clinical Investigation 2014 Feb 3 PMID: 24487588  

34.  Msaouel P, Lam AP, Gundabolu K, Chrysofakis G, Yu Y, Mantzaris I, Friedman E, Verma A, “Abnormal platelet count is an independent predictor of mortality in theelderly and is influenced by ethnicity.” Haematologica. 2014 Feb 7. PMID: 24510340  

35.  Kuo P, Leshchenko V, Fazzari M, Gellen T, Iqbal J, Baumgartner-Wennerholm S, Nygren L, Zhang F, Zhang W, Suh K, Goy A, Yang D, Chan W, Kahl B, Verma A, Gascoyne R, Kimby E, Sander B, Ye BH, Melnick A, Perumal D, He T, Parekh S, “High resolution Chromatin Immunoprecipitation (ChIP) sequencing reveals novel bindings targets and prognostic role for SOX11 in Mantle cell lymphoma”. Oncogene, 2014 Mar 31 PMID: 24681958  

36.  Hosono N, Makishima H, Jerez A, Yoshida K, Przychodzen B, McMahon S, Shiraishi Y, Chiba K, Tanaka H, Miyano S, Sanada M, Gómez-Seguí I, Verma AK, McDevitt MA, Sekeres MA, Ogawa S, Maciejewski JP, “Recurrent genetic defects on chromosome 7q in myeloid neoplasms.” Leukemia 2014 Jan 16. PMID: 24429498  

37.  Madzo J, Liu H, Rodriguez A, Vasanthakumar A, Sundaravel S, Caces DB, Looney TJ, Zhang L, Lepore JB, Macrae T, Duszynski R, Shih AH, Song CX, Yu M, Yu Y, Grossman R, Raumann B, Verma A, He C, Levine RL, Lavelle D, Lahn BT, Wickrema A, Godley LA, “Hydroxymethylation at Gene Regulatory Regions Directs Stem/Early Progenitor Cell Commitment during Erythropoiesis.” Cell Reports. 2013 Dec 24 PMID: 24373966  

38.  Ko YA, Mohtat D, Suzuki M, Park AS, Izquierdo MC, Han SY, Kang HM, Si H, Hostetter T, Pullman JM, Fazzari M, Verma A, Zheng D, Greally JM, Susztak K, “Cytosine methylation changes in enhancer regions of core pro-fibrotic genes characterize kidney fibrosis development.” Genome Biol. 2013 Oct 7;14(10):R108. PMID: 24098934  

39.  Pellagatti A, Benner A, Mills K, Cazzola M, Giagounidis AAN, Perry J, Malcovati L, Giovanni M, Porta D, Jädersten M,      Verma A, McDonald E, Killick S, Hellstrom-Lindberg E, Bullinger L, Wainscoat JS, Boultwood J, “Identification of gene expression based prognostic markers in the hematopoietic stem cells of patients with myelodysplastic syndromes.” JCO 2013 Oct 1;31(28):3557-64. PMID: 24002510  

40.  Lam AP, Gundabolu K, Sridharan A, Jain R, Msaouel P, Chrysofakis G, Yu Y, Friedman E, Price E, Schrier S, Verma AK, “Multiplicative interaction between mean corpuscular volume and red cell distribution width in predicting mortality of elderly patients with and without anemia.” Am J Hematol. 2013 Nov;88(11):E245-9. PMID: 23828763  

41.  Yang X, Song JH, Cheng Y, Wu W, Bhagat T, Yu Y, Abraham JM, Ibrahim S, Ravich Roland W, Khashab M, Singh VK, Shin EJ, Yang X, Verma A, Meltzer SJ, Mori Y, “Long Noncoding RNA HNF1A-AS1 Regulates Proliferation and Migration in Esophageal Adenocarcinoma Cells.” Gut 2013 Sep 2. PMID: 24000294  

42.  Bajpai M, Kessel R, Bhagat T, Nischal S, Yu Y, Verma A*, Das K *Co-Corresponding, “High resolution integrative analysis reveals widespread genetic and epigenetic changes after chronic in-vitro acid and bile exposure in Barrett's epithelium cells.” Genes Chromosome Cancer 2013 Oct 3. PMID: 24123713  

43.  Mehrotra S, Sharma B, Joshi S, Kroczynska B, Majchrzak B, Stein BL, McMahon B, Altman JK, Licht JD, Baker DP, Eklund EA, Wickrema A, Verma A, Fish EN, Platanias LC, “Essential role for the Mnk-pathway in the inhibitory effects of Type I interferons on myeloproliferative neoplasm (MPN) precursors.” JBC, 2013 Aug 16;288(33):23814-22 PMID: 23814052  

44.  Bhattacharyya, Si; Yu, Y; Suzuki, M; Campbell, N; Mazdo, J; Vasantkumar, A; Bhagat, T; Nischal, S; Christopeit, M; Parekh, S; Steidl, U; Godley, L; Maitra, A; Greally, J; Verma, A; “Genome wide hydroxymethylation tested using the HELP-GT assay shows redistribution in cancer.” Nucleic Acid Res 2013 Sep;41(16):e157 PMID: 23861445  

45.  Will B, Vogler TO, Bartholdy B, Garrett-Bakelman F, Mayer J, Barreyro L, Pandolfi A, Todorova TI, Okoye-Okafor UC, Stanley RF, Bhagat TD, Verma A, Figueroa ME, Melnick A, Roth M, Steidl U, “Satb1 regulates the self-renewal of hematopoietic stem cells by promoting quiescence and repressing differentiation commitment.” Nat Immunol. 2013 May;14(5):437-45. PMID: 23563689  

46.  Bhagat T, Zhou L, Sokol L, Caceres G, Gundabolu K, Gordon S, Mantzaris I, Gligich O, Yu Y, Bhattacharyya S, Jing X, Polineni R, Tamari R, Bhatia K, Pellagatti A , Boultwood J, Kambhampati S, Steidl U, Stein C, Ju W, Liu G, Kenny P, List A, Bitzer M, Verma A, “miR-21 mediates hematopoietic suppression in MDS by activating TGF-signaling” Blood 2013, Apr 11;121(15):2875-81. PMID: 23390194  

47.  Yu Y, Mo Y, Liu H, Bhattacharyya S, Ebenezer D, Sundaravel S, Caces B, Ulaszek J, Artz A, Nischal S, Bhagat T, Bathon K, Maqbool S, Suzuki M, Steidl U, Godley L, Skoultchi A, Greally J, Wickrema A, Verma A, “High resolution methylome analysis reveals widespread hypomethylation during human erythroid differentiation.” JBC 2013 Mar 29;288(13):8805-14. PMID: 23306203  

48.  Heuck C, Mehta J, Bhagat T, Gundabolu K, Yu Y, Khan S, Chrysofakis G, Schinke C, Tariman J, Vickrey E, Pulliam N, Nischal S, Zhou L, Bhattacharya S, Meagher R, Hu C, Maqbool S, , Suzuki M, Parekh S, Reu F, Steidl U, Greally J, Verma A*, Singhal S* Co-Corresponding, “Myeloma is characterized by stage specific alterations in DNA methylation that occur early during myelomagenesis.” Journal of Immunology 2013 Mar 15;190(6):2966-75. PMID: 23408834  

49.  Wu W, Bhagat T, Yang X, Song J, Cheng Y, Agarwal R, Abraham J, Ibrahim S, Bartenstein M, Hussain Z, Suzuki M, Yu Y, Eng C, Greally J, Verma A*, Meltzer SJ* Co-Corresponding , “Hypomethylation of Noncoding DNA Regions and Overexpression of the Long Noncoding RNA, AFAP1-AS1, in Barrett’s Esophagus and Esophageal Adenocarcinoma.” Gastroenterology 2013 May;144(5):956-966. PMID: 23333711  

50.  Nischal S, Bhattacharyya S, Christopeit N, Yu Y, Zhou L, Bhagat T, Sohal S, Will B, Mo Y, Suzuki M, Pardanani A, McDevitt M, Maciejewski J, Melnick A, Greally J, Steidl U, Moliterno A, Verma A, “Methylome profiling reveals distinct alterations in phenotypic and mutational subgroups of myeloproliferative neoplasms .” Cancer Res, 2012 Dec 27. PMID: 23066032  

51.  Will B, Zhou L, Vogler TO, Ben-Neriah S, Schinke C,Tamari R, Yu Y, Bhagat T, Bhattacharya S, Barreyro L, Heuck C, Mo Y, Parekh S, McMahon C, Pellagatti A, Boultwood J, Montagna C, Silverman L, Maciejewski J, Greally JM, Ye BH, List AF, Steidl C, Steidl U, Verma A, “Stem and progenitor cells in myelodysplastic syndromes show aberrant stage specific expansion and harbor genetic and epigenetic alterations.” Blood 2012; 120(10):2076-86. PMID: 22753872  

52.  Sokol L, Cripe L, Kantarjian H, Sekeres MA, Parmar S, Greenberg P, Goldberg SL, Bhushan V, Shammo J, Hohl R, Verma A, Garcia-Manero G, Li YP, Lowe A, Zhu J, List AF, “Randomized, dose-escalation study of the p38α MAPK inhibitor SCIO-469 in patients with myelodysplastic syndrome.” Leukemia. 2012 Sep 11. PMID: 23032694  

53.  Roth M, Will B, Simkin G, Narayanagari S, Barreyro L, Bartholdy B, Tamari R, Mitsiades CS, Verma A, Steidl U, “Eltrombopag inhibits the proliferation of leukemia cells via reduction of intracellular iron and induction of differentiation.” Blood. 2012 May 24. PMID: 22627766  

54.  Barreyro L, Will B, Bartholdy B, Zhou L, Todorova TI, Stanley RF, Ben-Neriah S, Montagna C, Parekh S, Pellagatti A, Boultwood J, Paietta E, Ketterling RP, Cripe L, Fernandez, Greenberg PL, Tallman MS, Steidl C, Mitsiades CS, Verma A, Steidl U, “Overexpression of IL-1 receptor accessory protein in stem and progenitor cells and outcome correlation in AML and MDS.” Blood. 2012 Aug 9;120(6):1290-8. PMID: 22723552  

55.  Jerez A, Sugimoto Y, Makishima H, Verma A, Jankowska AM, Przychodzen B, Visconte V, Tiu RV, O'Keefe CL, Mohamedali AM, Kulasekararaj AG, Pellagatti A, McGraw K, Muramatsu H, Moliterno AR, Sekeres MA, McDevitt MA, Kojima S, List A, Boultwood J, Mufti GJ, Maciejewski JP, “Loss of heterozygosity in 7q myeloid disorders: clinical associations and genomic pathogenesis.” Blood. 2012 Jun 21;119(25):6109-17. PMID: 22553315  

56.  Barta SK, Zou Y, Schindler J, Shenoy N, Bhagat TD, Steidl U, Verma A, “Synergy of sequential administration of a deglycosylated ricin A chain-containing combined anti-CD19 and anti-CD22 immunotoxin (Combotox) and cytarabine in a murine model of advanced acute lymphoblastic leukemia.” Leuk Lymphoma. 2012 Apr 18. PMID: 22448921  

57.  Stein BL, Williams DM, O'Keefe C, Rogers O, Ingersoll RG, Spivak JL, Verma A, Maciejewski JP, McDevitt MA, Moliterno AR, “Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes.” Haematologica. 2011 Oct;96(10):1462-9. Epub 2011 Jun 28. PMID: 21712540  

58.  Sharma B, Altman JK, Goussetis DJ, Verma AK, Platanias LC, “Protein kinase R as mediator of the effects of interferon (IFN) gamma and tumor necrosis factor (TNF) alpha on normal and dysplastic hematopoiesis.” J Biol Chem. 2011 Aug 5;286(31):27506-14. Epub 2011 Jun 9. PMID:1659535  

59.  Zhou L, Opalinska J, Sohal D, Yu Y, Mo Y, Bhagat T, Abdel-Wahab O, Fazzari M, Figueroa M, Alencar C, Zhang J, Kanbhampati S, Parmar S, Nischal S, Heuck C, Suzuki M, Friedman E, Pellagatti A, Boultwood J, Steidl U, Sauthararajah Y, Yajnik V, Gore SD, Platanias LC, Levine R, Melnick A, Wickrema A, Greally JM, Verma A, “Aberrant epigenetic and genetic marks are seen in myelodysplastic leucocytes and reveal DOCK4 as a candidate pathogenic gene on chr7q.” J Biol Chem. 2011 Apr 30. PMID: 21532034  

60.  Alvarez H, Opalinska J, Zhou L, Sohal D, Fazzari M, Yu Y, Montagna C, Montgomery E, Canto M, Dunbar K, Wang J, Roa J, Mo Y, Bhagat T, Ramesh K, Cannizzaro L, Mollenhauer J, Thompson R, Suzuki M, Meltzer S, Melnick A, Greally JM, Maitra A, Verma A, “Widespread hypomethylation occurs early and synergizes with gene amplification during esophageal carcinogenesis.” PLOS Genetics 2011 Mar;7(3) PMID: 21483804  

61.  L Zhou, C McMahon, T Bhagat, C Alencar, Y Yu, M Fazzari, D Sohal, C Heuck, K Gundabolu, C Ng, Y Mo, W Shen, A Wickrema, G Kong, E Friedman, L Sokol, G Mantzaris, A Pellagatti , J Boultwood, LC. Platanias. U Steidl, L Yan, JM Yingling, MM Lahn, A List, M Bitzer and A Verma, “Reduced SMAD7 leads to overactivation of TGF-beta signaling in MDS that can be reversed by a specific inhibitor of TGF-beta receptor I kinase.” Cancer Research 2011 Feb 1;71(3):955-63.PMID: 21189329  

62.  Joshi S, Sharma B, Kaur S, Majchrzak B, Ueda T, Fukunaga R, Verma AK, Fish EN, Platanias LC, “Essential role for Mnk kinases in type II interferon (IFNgamma) signaling and its suppressive effects on normal hematopoiesis.” J Biol Chem. 2011 Feb 25;286(8):6017-26.PMID: 21149447  

63.  Kroczynska B, Joshi S, Eklund EA, Verma A, Kotenko SV, Fish EN, Platanias LC, “Regulatory effects of ribosomal S6 kinase 1 (RSK1) in IFNλ signaling.” J Biol Chem. 2011 Jan 14;286(2):1147-56. Epub 2010 Nov 12.  

64.  Huh J, Tiu RV, Gondek LP, O'Keefe CL, Jasek M, Makishima H, Jankowska AM, Jiang Y, Verma A, Theil KS, McDevitt MA, Maciejewski JP, “Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome-wide single nucleotide polymorphism array analysis.” Genes Chromosomes Cancer. 2010 Apr;49(4):390-9. PMID: 20095039  

65.  Schinke C, Goel S, Bhagat TD, Zhou L, Mo Y, Gallagher R, Kabalka GW, Platanias LC, Verma A*, Das B, “Design and synthesis of novel derivatives of all-trans retinoic acid demonstrate the combined importance of acid moiety and conjugated double bonds in its binding to PML-RAR-alpha oncogene in acute promyelocytic leukemia.” Leuk Lymphoma. 2010 Jun;51(6):1108-14. PMID: 20536349  

66.  Pellagatti A, Cazzola M, Giagounidis A, Perry J, Malcovati L, Della Porta MG, Jädersten M, Verma A, Norbury C Hellström-Lindberg E, Wainscoat JS, Boultwood J, “ Deregulated gene expression pathways in myelodysplastic syndrome hematopoietic stem cells.” Leukemia. 2010 Apr;24(4):756-64. PMID: 20220779  

67.  Einstein F, Thompson RF, Bhagat TD, Fazzari MJ, Verma A, Barzilai N, Greally JM, “Cytosine methylation dysregulation in neonates following intrauterine growth restriction.” PLoS One. 2010 Jan 26;5(1):e8887 PMID: 20126273  

68.  Oda M., Glass J.L., Thompson R.F., Mo Y., Olivier E., Figueroa M.E., Selzer R.R., Richmond T.A., Zhang X., Dannenberg L., Green R., Melnick A., Hatchwell E., Bouhassira E., Verma A., Suzuki M., Greally J.M., “High-resolution genome-wide cytosine methylation profiling with simultaneous copy number analysis and optimization for limited cell numbers.” Nucleic Acids Res. 2009 Jul;37(12):3829-39. PMID: 19386619  

69.  Dumka D, Puri P, Carayol N, Lumby C, Balachandran H, Schuster K, Verma AK, Terada LS, Platanias LC, Parmar S, “Activation of the p38 Map kinase pathway is essential for the antileukemic effects of dasatinib.” Leuk Lymphoma. 2009 Dec;50(12):2017-29. PMID: 19672773  

70.  Kaur S, Sassano A, Joseph AM, Majchrzak-Kita B, Eklund EA, Verma A, Brachmann SM, Fish EN, Platanias LC, “Dual regulatory roles of phosphatidylinositol 3-kinase in IFN signaling.” J Immunol. 2008 Nov 15;181(10):7316-23. PMID: 18981154  

71.  Sohal D, Yeatts A, Ye K, Pellagatti A, Zhou L, Pahanish P, Mo Y, Bhagat T, Mariadason J, Boultwood J, Melnick A, Greally JM, Verma A, “Meta-analysis of microarray studies reveals a novel hematopoietic progenitor cell signature and demonstrates feasibility of inter-platform data integration.” PLOS One 2008 Aug 13;3(8):e2965 PMID: 18698424  

72.  Zhou L, Nguyen AN, Sohal D, Ma JY, Pahanish P, Gundabolu K, Hayman J, Chubak A, Mo Y, Bhagat T, Das B, Haghnazari E, Navas T, Parmar S, Kambhampati S, Pellagati A, Braunchweig I, Zhang YE, Wickrema A, Boultwood J, Platanias LC, Higgins LS, List A, Bitzer M, Verma A, “Inhibition of Transforming Growth Factor beta receptor I kinase can stimulate hematopoiesis in Myelodysplasia.” Blood 2008 Oct 15;112(8):3434-43 PMID: 18474728  

73.  Navas T, Zhou L, Estes M, Haghnazari E, Nguyen A, Mo Y, Pahanish P, Mohindru M, Cao T, Higgins L, Platanias LC, List A, Verma A, “Inhibition of p38a MAPK disrupts the pathological loop of proinflammatory factor production in the Myelodysplastic Syndrome bone marrow microenvironment.” Leukemia and Lymphoma 2008 Oct;49(10):1963-75  

74.  Zhou L, Opalinska J, Verma A, “p38 MAP kinase regulates stem cell apoptosis in human hematopoietic failure.”  Cell Cycle 2007, 1;6(5):534  

75.  Navas T, Mohindru M, Estes M, Ma JY, Sokol L, Pahanish P, Parmar S, Haghnazari E, Zhou L, Collins RC, Kerr I, Nguyen A, Xu Y, Platanias LC, List AA, Higgins LS, Verma A, “Inhibition of overactivated p38 MAPK can restore hematopoiesis in myelodysplastic syndrome progenitors.” Blood 2006, 15;108(13):4170-7  

76.  Verma A, and List A, “Cytokine Targets in Myelodysplastic syndromes.” Current Hematology Reports 2005 Nov;4(6):429-35   

77.  Katsoulidis E, Li Y, Yoon P, Sassano A, Altman J, Kannan-Thulasiraman P, Balasubramanian L, Parmar S, Varga J, Tallman MS, Verma A, Platanias LC, “Role of the p38 mitogen-activated protein kinase pathway in cytokine-mediated hematopoietic suppression in myelodysplastic syndromes.” Cancer Res. 2005 Oct 1;65(19):9029-37.  

78.  Trifilio S, Ortiz R, Pennick G, Verma A, Pi J, Stosor V, Zembower T, Mehta J, “Voriconazole therapeutic drug monitoring in allogeneic hematopoietic stem cell transplant recipients.” Bone Marrow Transplant. 2005 Mar;35(5):509-13.  

79.  Gidron A, Verma A, Doyle M, Boggio L, Evens A, Gordon L, Singhal S, Tallman M, Williams S, Winter J, Mehta J, “Can the stem cell mobilization technique influence CD34+ cell collection efficiency of leukapheresis procedures in patients with hematologic malignancies?” Bone Marrow Transplant 2005;35(3):243-6.  

80.  Parmar S, Katsoulidis E, Verma A, Li Y, Sassano A, Lal L, Majchrzak B, , Ravandi F, Tallman MS, Fish EN, Platanias LC, “Role of the p38 mitogen-activated protein kinase pathway in the generation of the effects of imatinib mesylate (STI571) in BCR-ABL-expressing cells.” J Biol Chem. 2004 Jun 11;279(24):25345-52  

81.  Verma A, Pedicano J, Trifilio S, Singhal S, Tallman M, Winter J, Williams S, Gordon L, Monreal J, Mehta J, “How long after neutrophil recovery should myeloid growth factors be continued in autologous hematopoietic stem cell transplant recipients?” Bone Marrow Transplant. 2004 Apr;33(7):715-9   

82.  Trifilio S, Verma A, Mehta J, “Antimicrobial prophylaxis in hematopoietic stem cell transplant recipients: heterogeneity of current clinical practice.” Bone Marrow Transplant. 2004 Apr;33(7):735-9  

83.  Verma A, Williams S, Trifilio S, Zembower T, Mehta J, “Successful treatment of concomitant pulmonary zygomycosis and aspergillosis with a combination of amphotericin B lipid complex, caspofungin, and voriconazole in a patient on immunosuppression for chronic graft-versus-host disease.” Bone Marrow Transplant. 2004 May;33(10):1065-6   

84.  Deonarain R, Verma A, Porter AC, Gewert DR, Platanias LC, Fish EN, “Critical roles for IFN-beta in lymphoid development, myelopoiesis, and tumor development: links to tumor necrosis factor alpha.” Proc Natl Acad Sci USA. 2003 Nov 11;100(23):13453-8  

85.  Verma A, Devine S, Morrow M, Chen YH, Mihalov M, Peace D, Stock W, Pursell K, Wickrema A, Yassine M, Jessop E, Van Besien K, “Low incidence of CMV viremia and disease after allogeneic peripheral blood stem cell transplantation. Role of pretransplant ganciclovir and post-transplant acyclovir.” Bone Marrow Transplant. 2003 May;31(9):813-6.   

86.  Verma A., Mohindru M., Deb D., Sassano A., Kambhampati S., Minucci S., Ravandi F., Kovakanalu D, Platanias L, “Activation of the Rac1 and p38 MAP kinase pathway in response to Arsenic trioxide.” Journal of Biological Chemistry 22;277(47):44988-95   

87.  Verma A, Sassano A, Deb D, Wickrema, A., VanBesien K., and Platanias L, “Blockade of p38 MAP kinase reverses cytokine mediated inhibition in aplastic anemia.” Journal of Immunology 2002, 168 (12) (Cutting edge section)   

88.  Verma A, Deb D.K., Sassano A., Uddine S., Wickrema A., Varga and Platanias LC, “Activation of the p38 mitogen activated protein kinase mediates suppressive effects of Type I interferons and transforming growth factor- on normal hematopoiesis.” Journal of Biological Chemistry 2002, 277(10):7726-35   

89.  Kambhampati S, Li Y, Verma A, Sassano A, Majchrzak B, Deb DK, Parmar S, Giafis N, Kalvakolanu DV, Rahman A, Uddin , Minucci, Tallman MS, Fish EN, Platanias LC, “Activation of protein kinase C-delta (PKC-delta) by All-trans-retinoic acid.” Journal of Biological Chemistry 2003 Aug 29;278(35):32544 PMID: 12805378  

90.  Uddin S, Sassano A, Deb D, Verma A, Majchrzak B, Rahman A, Malik A, Fish E, Platanias L, “Protein Kinase delta is activated by the Type I IFN receptor and mediates phosphorylation of Stat1 on serine 727.” Journal of Biological Chemistry 2002, 277(17):14408-16  

91.  Devine S, Hoffman R, Verma A, Shah R, Bradlow B, Stock W and Van Besien K, “Allogeneic blood cell transplantation following reduced intensity conditioning is effective therapy for older patients with myelofibrosis.” Blood 2002, 99(6):2255-8  

92.  Verma A, Stock W, Norohna S, Shah R, Bradlow B and Leonidas C, “Progressive Transformation of germinal centers: case reports and review of literature.” Acta Haematologica 2002;108(1):33-8.   

93.  Verma A, Stock W, Lait M, Ferrer K, Quinn J, and Platanias LC, “Actinomycosis presenting as a oral ulcer in a neutropenic patient.” Southern Medical Journal 2002 ,95(9):1105   

94.  Mayer IA, Verma A, Grumbach IM, Uddin S, Fujita S, Fish EN, Platanias LC, “The p38 MAP kinase pathway mediates the growth inhibitory effects of IFN-alpha in Chronic Myelogenous Leukemia cells.” The Journal of Biological Chemistry, 2001, 276(30):28570-7.  

95.  Sosman JA, Verma A, Moss S, Sorokin P, Blend M, Bradlow B, Chachlani N, Cutler D, Sabo R, Nelson M, Bruno E, Gustin D, Viana M, Hoffman R. “Interleukin 10-induced thrombocytopenia in normal healthy adult volunteers: evidence for decreased platelet production.” British Journal of Haematology, 2000, 111(1):104-11.  

96.  Verma A, Kokkat AJ, and Verma IC, “The prevalence of Thalessemia trait in school children in rural Haryana.” Indian Journal of Hematology Blood Transfusion, 1996,14:86-87.   

97.  Verma A, Vohra A, Maitra A, Banerjee M, Singh R, Mittal SK et al. “Epidemiology of chronic suppurative otitis media and deafness in a rural area for development of an intervention strategy.” Indian Journal of Pediatrics, 1995, 62(6):725-729.   

98.  Kokkat AJ, and Verma A, “Prevalence of seizures and paralysis in a rural community.” Journal of Indian Medical Assoc., 1998, 96(2):43-51.

99.  Verma A, Kokkat AJ, Kalia A, Kapoor SK, Rattan A, “Susceptibility of Staphylococcus aureus at a rural clinic.”(letter) Natl Med J India, 1997, 10(5):255. 

Review articles

1. Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A, “Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.” Leukemia, 2015 (In Press)

2. Shenoy N, Vallumsetla N, Zou Y, Galeas JN, Shrivastava M, Hu C, Susztak K, Verma A, “Role of DNA methylation in renal cell carcinoma.” J Hematol Oncol. 2015 Jul 22;8(1):88. PMID: 26198328

3. Verma A, Steidl U, “A synthetic lethal approach targeting mutant isocitrate dehydrogenase in acute myeloid leukemia.”      Nat Med. 2015;21:113-4. PMID: 25654599

4. Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y, “Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome.” Blood, 2014 Aug 7;124(6):873-81. PMID: 24923296

5. Gañán-Gómez I, Wei Y, Starczynowski DT, Colla S, Yang H, Cabrero-Calvo M, Bohannan ZS, Verma A, Steidl U, Garcia-Manero G, “Deregulation of innate immune and inflammatory signaling in myelodysplastic syndromes.” Leukemia. 2015 Mar 12. PMID: 25761935

6. Elias HK, Schinke C, Bhattacharyya S, Will B*, Verma A*, Steidl U*, *CoCorresponding, “Stem cell origin of myelodysplastic syndromes.” Oncogene 2013 Dec 16. PMID: 24336326

7. Das BC, Thapa P, Karki R, Das S, Mahapatra S, Liu TC, Torregroza I, Wallace DP, Kambhampati S, Van Veldhuizen P,      Verma A, Ray SK, Evans T, “Retinoic acid signaling pathways in development and diseases.” Bioorg Med Chem. 2014 Jan 15;22(2):673-83. PMID: 24393720

8. Pathak S, Roth M, Verma A*, Steidl U*, *CoCorresponding, “ Eltrombopag for the treatment of thrombocytopenia in patients with malignant and non-malignant hematologic disorders.” Expert Opin Drug Metab Toxicol. 2013 Dec;9(12):1667-75. PMID: 24215532

9. Khan H, Vale C, Bhagat T, Verma A, “Role of DNA methylation in the pathogenesis and treatment of myelodysplastic syndromes.” Semin Hematol. 2013 Jan;50(1):16-37. PMID: 23507481

10. Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK, “Linked-in: design and efficacy of antibody drug conjugates in oncology.” Oncotarget 2013 Mar;4(3):397-412. PMID: 23651630

11. Agarwal A, Polineni R, Hussein Z, Vigoda I, Bhagat TD, Bhattacharyya S, Maitra A, Verma A, “Role of epigenetic alterations in the pathogenesis of Barrett's esophagus and esophageal adenocarcinoma.” Int J Clin Exp Pathol. 2012;5(5):382-96. PMID: 22808291

12. Shenoy N, Kessel R, Bhagat TD, Bhattacharyya S, Yu Y, McMahon C, Verma A, “Alterations in the ribosomal machinery in cancer and hematologic disorders.” J Hematol Oncol. 2012 Jun 18;5:32. PMID: 22709827

13. Elias H, Verma A, “Activation of hypoxia signaling is marker of poor prognosis in myelodysplasia.” Leuk Lymphoma. 2012 Dec;53(12):2337-8. PMID: 22897726

14. Sharma A, Heuck C, Fazzari M, Mehta J, Singhal S, Greally JM, Verma A, “ DNA methylation alterations seen in myeloma as a model of epigenetic changes in cancer.” WIRES Systems Biology and Medicine 2010 Nov-Dec;2(6):654-69. PMID: 20890963

15. Schinke C, Mo Y, Yu Y, Amiri K, Sosman J, Greally JM, Verma A, “Aberrant DNA methylation in malignant melanoma.” Melanoma Research 2010, Aug; 20(4):253-65 PMID: 20418788

16. Kotla V, Goel S, Nischal S, Heuck C, Vivek K, Das B, Verma A, “Mechanism of action of lenalidomide in hematological malignancies.” J Hematol Oncol. 2009 Aug 12;2:36

17. Opalinska J, Zhou L, Verma A, “A new PML-RARs fusion transcript hints at the important role of PML dysregulation in the pathogenesis of APL.” Leukemia Research (Commentary) 2007, 48(3):443

18. Isufi I, Seetharam M, Sohal D, Zhou L, Opalinska J, Pahanish P, Verma A, “Transforming Growth Factor-beta Signaling in Normal and Malignant Hematopoiesis.” Journal of Interferon and Cytokine Research 2007, 27(7):543

19. Mohindru M, Verma A, “Engineered antibodies act as targeted therapies in cancer treatment.” Indian Journal of Pediatrics, 2005 Nov;72(11):943-7

20. Sassano A, Verma A, Platanias LC, “Mitogen-activated protein kinase pathways in interferon signaling.” Methods Molecular Medicine, 2005;116:135-50.

21. Mohindru M, Verma A, “Kinase inhibitors translate lab discoveries into exciting new cures for cancers.” Indian Journal of Pediatrics, 2004 Aug;71(8):713-8.

22. Verma A, Kambhampati S, Parmar S, Platanias LC, “Jak family of kinases in cancer.” Cancer Metastasis Rev. 2003 Dec;22(4):423-34.(rev)

23. Verma A and Platanias LC, “Signaling via the interferon-a receptor in chronic myelogenous leukemia cells.” Leukemia and Lymphoma 2002, 44:703-709

24. Verma A and Stock W, “Management of adult lymphoblastic leukemia: moving toward a risk-adapted approach.” Current Opinion in Oncology, 2001, 13:14-20

25. Verma A and Gupta YK, “The search for a super oral rehydration solution (0RS).” Drugs: News and Views, 1995, 3(2):129-132.

 
Click here to log in